Acalabrutinib in chronic lymphocytic leukemia

Expert Opin Pharmacother. 2023 Apr;24(5):545-549. doi: 10.1080/14656566.2023.2194486. Epub 2023 Mar 23.

Affiliations

¹ Hematology Unit, Azienda Ospedaliera Annunziata, Cosenza, Italy.
² Department of Experimental and Clinical Medicine, University "Magna Graecia" of Catanzaro, Catanzaro, Italy.
³ Direzione Generale, Ospedaliera Annunziata, Cosenza, Italy.
⁴ Scientific Directorate IRCCS of Reggio Emilia, Reggio Emilia, Italy.
⁵ Biotechnology Research Unit, AO of Cosenza, Cosenza, Italy.

PMID: 36943916
DOI: 10.1080/14656566.2023.2194486

No abstract available

Keywords: Acalabrutinib; chronic lymphocytic leukemia; therapy.

Publication types

Editorial
Comment

MeSH terms

Benzamides / adverse effects
Humans
Leukemia, Lymphocytic, Chronic, B-Cell* / drug therapy
Protein Kinase Inhibitors / adverse effects
Pyrazines / adverse effects

Substances

acalabrutinib
Benzamides
Pyrazines
Protein Kinase Inhibitors